Should You Buy Viking Therapeutics Before Nov. 5?

Viking Therapeutics (NASDAQ: VKTX) leaped onto center stage early last year when it announced promising news about a candidate addressing an area of soaring demand: weight loss. The biotech then said its weight loss candidate, VK2735, met the goals of its phase 2 study. Investors realized it would be continuing into later-stage trials -- and the stock price surged more than 120% in one trading session.Viking remains on track, with the injectable candidate in phase 3 trials and an oral version now in phase 2. As for the stock price, it lost momentum and fell 47% over the past year. But in recent times, the positive momentum has gained some ground. The shares have climbed about 16% over the past three months.Now, heading into the first week of November, Viking faces a couple of potential catalysts. Should you buy the stock before Nov. 5 to possibly benefit? Let's find out.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool